{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:35:32Z","timestamp":1788831332086,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T00:00:00Z","timestamp":1501632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T00:00:00Z","timestamp":1501632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2609-0","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T00:48:46Z","timestamp":1501634926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest\u00ae macromethod among patients with MRSA bloodstream infections: a pilot study"],"prefix":"10.1186","volume":"17","author":[{"given":"Dmitriy M.","family":"Martirosov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique R.","family":"Bidell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjunath P.","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc H.","family":"Scheetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Faragon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise-Anne","family":"McNutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Lodise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,2]]},"reference":[{"issue":"3","key":"2609_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/cid\/cir034","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus Aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285\u201392.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2609_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/jac\/47.4.399","volume":"47","author":"M Wootton","year":"2001","unstructured":"Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus Aureus in a UK hospital. J Antimicrob Chemother. 2001;47(4):399\u2013403.","journal-title":"J Antimicrob Chemother"},{"key":"2609_CR3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1086\/381093","volume":"38","author":"PG Charles","year":"2004","unstructured":"Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus Aureus. Clin Infect Dis. 2004;38:448\u201351.","journal-title":"Clin Infect Dis"},{"key":"2609_CR4","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1128\/AAC.00380-13","volume":"57","author":"AM Casapao","year":"2013","unstructured":"Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, et al. Clinical outcomes in patients with heterogeneous vancomycin-intermediate Staphylococcus Aureus (hVISA) bloodstream infection. Antimicrob Agents Chemother. 2013;57:4252\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"2609_CR5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/0196-6553(88)90053-3","volume":"16","author":"JS Garner","year":"1988","unstructured":"Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128\u201340.","journal-title":"Am J Infect Control"},{"key":"2609_CR6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1128\/JCM.01508-06","volume":"45","author":"M Wootton","year":"2007","unstructured":"Wootton M, MacGowan AP, Walsh TR, Howe RA. A multicenter study evaluating the current strategies for isolating Staphylococcus Aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol. 2007;45:329\u201332.","journal-title":"J Clin Microbiol"},{"key":"2609_CR7","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/cid\/ciu398","volume":"59","author":"TP Lodise","year":"2014","unstructured":"Lodise TP, Drusano GL, Zasowski E, Dihmess A, Lazariu V, Cosler L, et al. Vancomycin exposure in patients with Methicillin-resistant Staphylococcus Aureus bloodstream infections: how much is enough? Clin Infect Dis. 2014;59:666\u201375.","journal-title":"Clin Infect Dis"},{"key":"2609_CR8","unstructured":"Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard\u2014Ninth Edition M07-A9. Wayne: CLSI; 2012."},{"key":"2609_CR9","volume-title":"ADAPT 5 User's guide: pharmacokinetic\/Pharmacodynamic systems analysis software","author":"DZ D'Argenio","year":"2009","unstructured":"D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 User's guide: pharmacokinetic\/Pharmacodynamic systems analysis software. Los Angeles: Biomedical Simulations Resource; 2009."},{"key":"2609_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1128\/AAC.01653-13","volume":"58","author":"MN Neely","year":"2014","unstructured":"Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014;58:309\u201316.","journal-title":"Antimicrob Agents Chemother"},{"key":"2609_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","volume":"17","author":"WA Craig","year":"2003","unstructured":"Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin N Am. 2003;17:479\u2013501.","journal-title":"Infect Dis Clin N Am"},{"key":"2609_CR12","unstructured":"Craig WA, Andes DA. Abstracts of the forty-sixth annual meeting of the Interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, 2006. Abstract A-644. In:  In vivo pharmacodynamics of vancomycin against VISA, heteroresistant VISA (hVISA) and VSSA in the neutropenic murine thigh-infection model. Washington: American Society for Microbiology."},{"key":"2609_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1128\/AAC.01133-10","volume":"55","author":"SJ van Hal","year":"2011","unstructured":"van Hal SJ, Paterson DL. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus Aureus isolates. Antimicrob Agents Chemother. 2011;55:405\u201310.","journal-title":"Antimicrob Agents Chemother"},{"key":"2609_CR14","unstructured":"Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States. Department of Health and Human Services; 2013. \n                    http:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/pdf\/ar-threats-2013-508.pdf\n                    \n                  . Accessed 6 Feb 2017"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2609-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-017-2609-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2609-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T11:21:03Z","timestamp":1589455263000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2609-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,2]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2609"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2609-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,2]]},"assertion":[{"value":"8 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in accordance with the AMCH Institutional Review Board. Patient consent to participate was waived.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"T.P.L. is a consultant for Cubist. M.H.S. has served on a consulting board for Trius Pharmaceuticals with all proceeds being donated to Midwestern University. He is a grant-funded investigator for Cubist Pharmaceutical for an antimicrobial stewardship study. All other authors: none to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"534"}}